Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

Table 1 Patient characteristics

Patient	Gender	Age (years)	FAB	Karyotype	Molecular mutations
					FLT3-ITD	MLL-PTD	NPM1
# 1	M	64	M2	46, XY	-	-	+
# 2	M	71	M4	46, XY	+	-	+
# 3	M	45	M3v	46, XY, t(15;17)	-	-	-
# 4	F	70	M1	46, XX	-	-	-
# 5	M	69	M4	46, XY	-	-	+
# 6	F	23	M2	46, XX	+	-	+
# 7	M	36	M3	46, XY, t(15;17)	-	-	-
# 8	F	34	M3	46, XX, t(15;17)	-	-	-
# 9	M	51	M3	46, XY, t(15;17)	-	-	-
# 10	F	39	M2	46, XX	-	-	-
# 11	M	48	M2	46, XY	-	-	-
# 12	M	62	M4	46, XY	+⁽¹⁾	-	+
# 13	M	37	M3v	46, XY, t(15;17)	+	-	-
# 14	M	63	M4	46, XY	-	-	-
# 15	M	72	M2	45, X, (-Y)	+	-	+
# 16	F	70	M2	46, XX, t(8;21)	-	-	-
# 17	F	32	M5a	46, XX	-	-	-
# 18	M	55	M4	46, XY	+	-	+
# 19	M	67	M0	51, XY, +9, +10, +11, +13 × 2, +3,	-	-	-
# 20	F	28	sAML	46, XY	-	-	+

Abbreviations: M, male; F, female; FAB, French-American-British classification system
(1) AML #12 = FLT3-TKD mutation

ISSN: 1479-5876